Product nameAnti-ADAMTS13 antibody
See all ADAMTS13 primary antibodies
DescriptionRabbit polyclonal to ADAMTS13
Specificityab28274 recognises the metalloproteinase domain of ADAMTS13.
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat
Synthetic peptide corresponding to Human ADAMTS13.
(Peptide available as
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.4
Concentration information loading...
PurityImmunogen affinity purified
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab28274 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/5000. Detects a band of approximately 190 kDa (predicted molecular weight: 154 kDa).Can be blocked with ADAMTS13 peptide (ab41249). 1/1000 when using colorimetric substrates such as BCIP/NBT - 1/5000, when using chemiluminescent substrates. Glycosylation and the abundance of cysteine residues gives ADAMTS 13 an apparent molecular weight of 190 kDa on reduced SDS PAGE gels. Several bands at 110-190 kDa are observed on Western blots, possibly indicating differentially processed ADAMTS 13. Dilution optimised using Chromogenic detection.|
FunctionCleaves the vWF multimers in plasma into smaller forms.
Tissue specificityPlasma. Expressed primarily in liver.
Involvement in diseaseDefects in ADAMTS13 are the cause of thrombotic thrombocytopenic purpura congenital (TTP) [MIM:274150]; also known as Upshaw-Schulman syndrome (USS). A hematologic disease characterized by hemolytic anemia with fragmentation of erythrocytes, thrombocytopenia, diffuse and non-focal neurologic findings, decreased renal function and fever.
Sequence similaritiesContains 2 CUB domains.
Contains 1 disintegrin domain.
Contains 1 peptidase M12B domain.
Contains 8 TSP type-1 domains.
DomainThe pro-domain is not required for folding or secretion and does not perform the common function of maintening enzyme latency.
The spacer domain is necessary to recognize and cleave vWF. The C-terminal TSP type-1 and CUB domains may modulate this interaction.
modificationsMay contain a C-mannosylation site and O-fucosylation sites in the TSP type-1 domains.
The precursor is processed by a furin endopeptidase which cleaves off the pro-domain.
- Information by UniProt
- A disintegrin and metalloproteinase with thrombospondin motifs 13 antibody
- A disintegrin like and metalloprotease (reprolysin type) with thrombospondin type 1 motif 13 antibody
- A disintegrin like and metalloprotease with thrombospondin type 1 motif 13 antibody
All lanes : Anti-ADAMTS13 antibody (ab28274) at 1 µg/ml
Lane 1 : Recombinant Human ATS-13 at 0.08 µg
Lane 2 : Recombinant Human ATS-13 at 0.04 µg
Lane 3 : Recombinant Human ATS-13 at 0.02 µg
Predicted band size: 154 kDa
Glycosylation and the abundance of cysteine residues gives ADAMTS-13 an apparent molecular weight of about 190 kDa on reduced SDS PAGE gels.
This product has been referenced in:
- Garland KS et al. Removal of the C-Terminal Domains of ADAMTS13 by Activated Coagulation Factor XI induces Platelet Adhesion on Endothelial Cells under Flow Conditions. Front Med (Lausanne) 4:232 (2017). WB . Read more (PubMed: 29326937) »
- Tauchi R et al. ADAMTS-13 is produced by glial cells and upregulated after spinal cord injury. Neurosci Lett 517:1-6 (2012). Read more (PubMed: 22425718) »